A Phase 1 interventional study of Advagraf® and Generic tacrolimus in Kidney Transplant, sponsored by Sandoz. Withdrawn at 13 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-17.
Sponsored by Sandoz (formerly part of Novartis) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Study to compare pharmacokinetics of tacrolimus prolonged-release (PR) capsules and Advagraf® PR capsules in stable kidney transplant patients.
Initially, patients will enter a short screening period, and those who continue to meet the inclusion and exclusion criteria will be randomized to receive either test or reference medicinal product in Period 1. In period 2 they will switch to the other formulation. During the whole treatment period four full-pharmacokinetics profiles will be established.
Sandoz is the lead sponsor of 139 studies on the registry; none are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.
First submitted before Sandoz left Novartis.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In Period 1 patients will receive branded tacrolimus (Advagraf®) orally once-a-day and in Period 2 patients will receive the generic tacrolimus (Sandoz) orally once-a-day.
Drug: Advagraf® · Drug: Generic tacrolimus
In Period 1 patients will receive the generic tacrolimus (Sandoz) orally once-a-day and in Period 2 patients will receive branded tacrolimus (Advagraf®) orally once-a-day.
Drug: Advagraf® · Drug: Generic tacrolimus
Advagraf®1 mg and 5 mg prolonged-release hard capsules once daily (reference medicinal product).
Tacrolimus 1 mg and 5 mg prolonged release hard capsules (Sandoz) once daily (test medicinal product)
AUC(0-τ)ss
Area under the whole blood concentration curve during a dosage interval (τ=24 hours) at steady state
Time frame: Day 21 of each treatment period
Cmax,ss
Maximum whole blood concentration at steady state
Time frame: Day 21 of each treatment period
AUC(0-τ)ss
Area under the whole blood concentration curve during a dosage interval (τ=24 hours) at steady state
Time frame: Day 14 of each treatment period
Cmax,ss
Maximum whole blood concentration at steady state
Time frame: Day 14 of each treatment period
Cmin,ss
Minimum whole blood concentration at steady state
Time frame: Days 14 and 21 of each treatment period
Cτ,ss
Concentration at the end of the dosing interval at steady state
Time frame: Days 14 and 21 of each treatment period
Cav
Average concentration during a dosing interval: AUC(0-τ)/τ
Time frame: Days 14 and 21 of each treatment period
Tmax,ss
Time to reach maximum (peak) plasma concentration at steady state
Time frame: Days 14 and 21 of each treatment period
AUC(0-τ)ss coefficient of variation
Intra-patient pharmacokinetics variability evaluated by calculating AUC(0-τ)ss coefficient of variation
Time frame: Days 14 and 21 of each treatment period
Cmax,ss coefficient of variation
Intra-patient pharmacokinetics variability evaluated by calculating Cmax,ss coefficient of variation
Time frame: Days 14 and 21 of each treatment period
% Fluctuation
Degree of fluctuation of the analyte concentration levels over one dosing interval: 100\*(Cmax,ss - Cmin,ss)/Cav.
Time frame: Days 14 and 21 of each treatment period
%Swing
Degree of change of the analyte concentration levels over one dosing interval: 100\*(Cmax,ss - Cτ,ss)/Cτ,ss.
Time frame: Days 14 and 21 of each treatment period
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2019; primary completion for May 2020, 8 months later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tacrolimus